



WHEN BLEEDS HAPPEN
**Will you be
prepared?**

Dallas who lives with GT with resistance to platelets and uses NovoSeven[®] RT.

What is NovoSeven[®] RT?

NovoSeven[®] RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia with a decreased or absent response to platelet transfusions
- Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven[®] RT?

NovoSeven[®] RT may cause serious side effects, including:

- **Serious blood clots** that form in veins and arteries with the use of NovoSeven[®] RT have been reported
- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven[®] RT



Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven[®] RT
Coagulation Factor VIIa
(Recombinant)





About Glanzmann's thrombasthenia (GT)

GT is a rare genetic disorder that affects about 1 in 1 million people. It is inherited from both parents and can occur in both men and women. 53% of GT patients experience their first bleed symptoms by age 1 year and 85% by age 14.^a

Your blood contains small cells called platelets. When you begin to bleed, there are proteins on the platelets that help your blood clot properly by helping platelets connect to each other. Those platelets stick together to form a "plug" that stops a bleed. Due to the genetic mutation people with GT are born with, platelets are not able to properly function. This means the platelets cannot form a plug to stop a bleed.

Bypassing agents help platelets work around the genetic mutation in order to help your body form normal clots.

^aBased on data from Glanzmann's Thrombasthenia Registry (GTR).

Common signs and symptoms of GT

Those with GT mainly have skin and mucous membrane types of bleeding. The most common signs of GT include:

- Easy bruising
- Bleeding from the nose or gums
- Bleeding beneath the skin that causes red or purple spots to form on the skin (petechiae)
- Prolonged bleeding from injury, trauma, or surgery (including dental work)
- Tissue bleeding that results in swelling (hematoma)
- Abnormally heavy menstrual bleeding
- Increased risk of heavy blood loss during pregnancy and childbirth

Less common bleeding episodes can happen inside the skull or joints. Additionally, 1 in 4 people with GT have gastrointestinal bleeding.

Scan the QR code to learn more about bleed identification and management.



It's important to have an on-demand treatment with you to stop bleeds whenever and wherever they happen.

Cathy who has GT with resistance to platelets and uses NovoSeven® RT.



The one and only NovoSeven® RT

The Recombinant Factor VIIa (rFVIIa)

TRUSTED BY PATIENTS FOR OVER 30 YEARS^a

**FIRST
&
ONLY**

rFVIIa approved for:
GT when platelets don't work^b

rFVIIa approved for:

- All ages (children, adolescents, and adults)
- Before, during, and after surgery

Over **140** GT patients and **518** GT bleeds have been treated in clinical trials and registry data^c

^aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

^bFDA approval received in 2014 for GT.

^cIn clinical trials and data collected from registries, NovoSeven® RT was studied in people with hemophilia A or B with inhibitors, Glanzmann's thrombasthenia, congenital factor VII deficiency, and acquired hemophilia.

Important Safety Information (*cont'd*)

What is the most important information I should know about NovoSeven® RT? (*cont'd*)

- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
- You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

Please see Important Safety Information throughout.

Please see Prescribing Information at

<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)




Kali who lives with GT with resistance to platelets and uses NovoSeven® RT.



Controls bleeds, whenever and wherever they happen

Proven **effective** to treat GT at home^a



In all bleeds in Glanzmann's thrombasthenia^b

266 episodes, all treatments

Effectiveness in children^b

- 94% bleed control in patients 0-12 years, (N=43) for 157 bleeding episodes, (N=15) for 19 surgical procedures
- 100% bleed control in patients >12-16 years, (N=8) for 17 bleeding episodes, (N=3) for 3 surgical procedures

^aWhen platelets don't work.

^bNovoSeven® RT only and NovoSeven® RT with platelets and/or antifibrinolytics. Effectiveness seen in a prospective, observational, multinational study (from an analysis of published cases and people who took part in trials and registries).

Important Safety Information (cont'd)

What should I tell my healthcare provider before using NovoSeven® RT?

- Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
 - congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
 - are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
 - history of heart or blood vessel diseases

Please see Important Safety Information throughout.

Please see Prescribing Information at

<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)



The **one** and **only** NovoSeven® RT

The **only** FDA-approved bypassing agent for people with Glanzmann's thrombasthenia^a

^aWith refractoriness to platelet transfusions, with or without antibodies to platelets.

Established safety profile that comes with experience^b

- Low <0.2% rate of unintended blood clots reported in clinical trials^c
 - Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
- Recombinant manufacturing minimizes the possibility of viral contamination
 - Made without any human blood or plasma

^bCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999 for CHWI and FVIIId.

^cThrombotic events reported for people with GT based on registry data collected.

Important Safety Information (cont'd)

What should I tell my healthcare provider before using NovoSeven® RT? (cont'd)

- Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

Effective in surgeries and procedures

NovoSeven® RT is approved by the FDA for treating people with Glanzmann's thrombasthenia^a before, during, and after surgery and procedures.

^aWhen platelets don't work.

In a clinical trial, NovoSeven® RT was **proven to effectively control bleeds throughout the surgery process.**



During surgical procedures

160 procedures, all treatments

Effectiveness in children in a large observational study

- 100% effective in surgical procedures in children 0-16 years, (N=18) for 22 surgical procedures

Talk with your doctor for more information about controlling bleeds before, during, and after surgery or a procedure.



Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)



Emily who lives with GT with resistance to platelets and uses NovoSeven® RT.



Experience **fast bleed control** with NovoSeven® RT

Fast to infuse

Fast infusions mean that NovoSeven® RT gets to work stopping bleeds quickly.

- NovoSeven® RT is given as an intravenous (IV) bolus injection **over 2-5 minutes**, depending on the dose administered



- NovoSeven® RT can be redosed every 2-6 hours, which lets you dose as needed to get bleeds under control fast
- NovoSeven® RT is room temperature stable up to 77 °F, so there's no need to refrigerate^a
- Your hemophilia treatment center (HTC) and your doctor will help you decide which dosing schedule is best for you

^aNovoSeven® RT should be stored between 36 °F and 77 °F. For complete storage information, please see Prescribing Information.

Important Safety Information (*cont'd*)

What are the possible side effects of NovoSeven® RT?

- The most common and serious side effects are blood clots
- Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please see Important Safety Information throughout.
Please see Prescribing Information at
<https://www.novo-pi.com/novosevenrt.pdf>

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)



Less time spent dosing. **More time** for you.

Available in 4 different vial sizes to help meet your needs.



Simple dosing delivers the results you need.

90 mcg/kg

- **NovoSeven® RT can be redosed every 2-6 hours**, which lets you dose as needed to get bleeds under control fast
- **No daily dose restrictions**




With MixPro®, preparing a dose is as quick as

ATTACH, TWIST, AND MIX^a

- Fast to mix, fast to infuse, and fast to control bleeds

Scan to watch the video and see how to prepare a dose with MixPro®



Small, compact size lets NovoSeven® RT go with you^b



^aPlease see Instructions for Use for complete instructions on preparing a dose.

^bNovoSeven® RT should be stored between 36 °F and 77 °F.

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

- **Serious blood clots** that form in veins and arteries with the use of NovoSeven® RT have been reported
- Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

Please see Important Safety Information throughout.
Please see Prescribing Information at <https://www.novo-pi.com/novosevenrt.pdf>



FIRST & ONLY

rFVIIa approved for:

Glanzmann's thrombasthenia when platelets don't work^a

rFVIIa approved for:

- All ages (children, adolescents, and adults)
- Before, during, and after surgery

- ✓ **140 GT patients and 518 GT bleeds treated in clinical trials and registry data**
- ✓ **Proven control of the mildest to the most life-threatening bleeds**
- ✓ **Fast bleed control for all ages**
- ✓ **Proven effective to treat GT at home**

Kali

who lives with GT with resistance to platelets and uses NovoSeven® RT.



Trusted to stop bleeds **for over 30 years^b**

^aFDA approval received in 2014 for GT.

^bCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

Important Safety Information (cont'd)

What is the most important information I should know about NovoSeven® RT? (cont'd)

- Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
- You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

Please see Important Safety Information throughout.

Please see Prescribing Information at <https://www.novo-pi.com/novosevenrt.pdf>



Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

MixPro® and NovoSeven® are registered trademarks of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

© 2022 Novo Nordisk Printed in the U.S.A.

US22NSVN00103 December 2022

NovoSeven® RT
Coagulation Factor VIIa
(Recombinant)

